Scholarlink

<p>Outer surface protein A (OspA) is a ~30 kDa lipoprotein displayed on the surface of <i>Borrelia burgdorferi sensu lato</i>, the etiological agent of Lyme disease. Here we report on the preclinical evaluation of OspA-encoding nucleoside-modified mRNA lipid nanoparticle (OspA mRNA-LNP) vaccines for the prevention of Lyme disease. Crystallographic and binding studies using a panel of transmission-blocking antibodies confirmed that the mRNA-encoded OspA serotype 1 (ST1) expressed in mammalian cells assumes its native structure and retains known protective epitopes. Immunization of mice with OspA ST1 mRNA-LNP elicited functional serum antibodies that promoted spirochete agglutination and complement-dependent borreliacidal activity in vitro. We also examined the impact of combining ST1 OspA mRNA with OspA STs 2-7, which are associated with predominant <i>Borrelia</i> genospecies in Europe (<i>B. garinii, B. afzelii, and B. bavariensis)</i>. The additional six STs mRNA did not interfere with ST1 antibody titers and functionality. Finally, mice vaccinated two or three times with different dose levels of OspA ST1 mRNA-LNP or with the heptavalent mRNA vaccine were protected against <i>B. burgdorferi</i> infection in a tick-mediated challenge model. The monovalent and the heptavalent OspA mRNA vaccines (mRNA-1982 and mRNA-1975, respectively) are currently undergoing testing in a Phase 1 clinical trial (NCT05975099).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Monovalent and multivalent OspA mRNA-LNP vaccines elicit functional antibodies and protect against Borrelia burgdorferi in mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月5日

查看全文
  • Meredith B. Finn,
  • Graham Willsey,
  • Carol Lyn Piazza,
  • Luke Clendenen,
  • Muskan Shrestha,
  • Stephanie Soee You,
  • Lingzhi Ma,
  • Yukti Dhingra,
  • Adrian R. Laciak,
  • Kevin A. Uggowitzer,
  • Joshua M. Obiero,
  • Grace Freeman-Gallant,
  • Harini Natarajan,
  • Shannon Green,
  • Elham Pirayesh,
  • Yen-Ting Lai,
  • Sunny Himansu,
  • Andrea Carfi,
  • Linden T. Hu,
  • Nicholas Mantis,
  • Obadiah Plante,
  • Christina Dold

摘要

Outer surface protein A (OspA) is a ~30 kDa lipoprotein displayed on the surface of Borrelia burgdorferi sensu lato, the etiological agent of Lyme disease. Here we report on the preclinical evaluation of OspA-encoding nucleoside-modified mRNA lipid nanoparticle (OspA mRNA-LNP) vaccines for the prevention of Lyme disease. Crystallographic and binding studies using a panel of transmission-blocking antibodies confirmed that the mRNA-encoded OspA serotype 1 (ST1) expressed in mammalian cells assumes its native structure and retains known protective epitopes. Immunization of mice with OspA ST1 mRNA-LNP elicited functional serum antibodies that promoted spirochete agglutination and complement-dependent borreliacidal activity in vitro. We also examined the impact of combining ST1 OspA mRNA with OspA STs 2-7, which are associated with predominant Borrelia genospecies in Europe (B. garinii, B. afzelii, and B. bavariensis). The additional six STs mRNA did not interfere with ST1 antibody titers and functionality. Finally, mice vaccinated two or three times with different dose levels of OspA ST1 mRNA-LNP or with the heptavalent mRNA vaccine were protected against B. burgdorferi infection in a tick-mediated challenge model. The monovalent and the heptavalent OspA mRNA vaccines (mRNA-1982 and mRNA-1975, respectively) are currently undergoing testing in a Phase 1 clinical trial (NCT05975099).